A New Challenge in Nrf2 Activation

Researchers at Nanjing Medical University in China have initiated a Phase 2/3 clinical trial (NCT07548996) to evaluate the use of dimethyl fumarate (DMF), a widely used treatment for multiple sclerosis, to preserve pancreatic beta-cell function in patients with Type 1 Diabetes Mellitus (T1DM). This study represents an innovative approach by stimulating the Nrf2 activation pathway, which induces immune regulation and antioxidant effects, to protect the pancreas from autoimmune attacks. DMF is already an FDA-approved drug for multiple sclerosis under the brand name 'Tecfidera' by Biogen, and its safety has been established. If the clinical trial is successful, it could become a game-changer, complementing existing insulin therapies.

Clinical Design and Patient Selection Strategy

This clinical trial will involve 96 adult patients aged 18 to 65 with confirmed autoantibodies and a C-peptide level of 200 pmol/L or higher, which indicates residual pancreatic secretory capacity. The treatment group will receive dimethyl fumarate enteric-coated capsules in addition to standard insulin therapy, while the control group will continue with insulin therapy alone. The primary endpoint will be the change in the area under the curve (AUC) of C-peptide during a mixed-meal tolerance test (MMTT) after 24 weeks of drug administration, measured at 48 weeks after enrollment.

Repurposing a Failed Drug and Addressing Unmet Needs

The global market for Type 1 Diabetes is estimated to be between $16 billion and $40 billion. However, therapeutic options to prevent the destruction of insulin-producing cells remain limited. Recently, another low-cost drug repurposing candidate, the calcium channel blocker verapamil, failed to demonstrate statistically significant preservation of C-peptide in the 2025 Ver-A-T1D Phase 2 clinical trial. This failure has created a significant gap in the development of oral pancreatic beta-cell protective agents. Therefore, this dimethyl fumarate clinical trial is attracting significant attention from the global academic and market communities, as it aims to determine whether an affordable oral agent can replace expensive immunotherapies.

Competition with Approved Leading Products

Currently, the only approved disease-modifying therapy (DMT) for Type 1 Diabetes worldwide is Tzield (teplizumab), a CD3-targeted monoclonal antibody acquired by Sanofi through the acquisition of Provention Bio for $2.9 billion. However, Tzield has limited patient accessibility due to its high cost of approximately $193,000 per 14-day treatment course and its intravenous administration. If dimethyl fumarate demonstrates significant C-peptide preservation in this clinical trial and overcomes concerns about adverse effects such as lymphopenia, it has the potential to rapidly penetrate the market as a next-generation treatment option that offers both convenience and affordability.